Loading...

Quantum BioPharma Ltd.

QNTM•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$20.25
$-1.47(-6.77%)

Quantum BioPharma Ltd. (QNTM) Stock Overview

Explore Quantum BioPharma Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.4/100

Key Financials

Market Cap58.9M
P/E Ratio-1.10
EPS (TTM)$-13.22
ROE-1.88%
Fundamental Analysis

AI Price Forecasts

1 Week$16.18
1 Month$7.72
3 Months$3.63
1 Year Target$8.74

QNTM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Quantum BioPharma Ltd. (QNTM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $8.74.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.10 and a market capitalization of 58.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for QNTMStats details for QNTM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for QNTMAnalyst Recommendations details for QNTM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

CEO

Zeeshan Saeed

Headquarters

55 University Ave., Toronto, ON

Founded

1970

Frequently Asked Questions

;